[3] Lobeglitazone is used to assist regulation of blood glucose level of diabetes mellitus type 2 patients.

[4] Lobeglitazone was approved by the Ministry of Food and Drug Safety (Korea) in 2013, and the postmarketing surveillance is on progress until 2019.

In the dose range, the mean half-life was 10.3 h.[2] Urine excretion was negligible amount in elimination of lobeglitazone in rat and human.

[6] Lobeglitazone was primarily distributed to the liver with tissue-to-plasma concentration ratio as 5.59, and less to heart, lung, and fat.

[1] Among six major membrane transporters recommended by the United States Food and Drug Administration, lobeglitazone interacts with OATP1B1, OAT3, and MDR1.